Hepion pharmaceuticals, inc. (CTRV)
Income statement / Yearly
Dec'19Dec'18Jun'17Jun'16Jun'15Jun'14Mar'14
Costs and expenses:
Research and development

3,184

7,593

13,651

15,019

8,403

314

113

General and administrative

4,586

7,000

7,371

5,786

5,556

1,357

829

Total operating expenses

7,770

14,594

21,023

20,805

13,959

-

-

Loss from operations

-7,770

-14,594

-21,023

-20,805

-13,959

-1,672

-942

Other income (expense):
Change in fair value of debt

-179

-108

-

-

-

-

-

Interest expense

554

339

-

-

-

-

-

Change in fair value of derivative instruments-warrants and contingent consideration

558

5,056

4,224

3,806

-

-

-

Interest expense

-

-

-

-

-

12

13

Total other income (expense)

-

-

-

3,806

-387

-3,608

-8,859

Change in fair value of derivative instruments-warrants

-

-

-

-

387

3,595

8,846

Loss before income taxes

-7,946

-9,985

-16,799

-16,998

-

-

-

Income tax benefit

-1,227

-536

-1,908

-

-

-

-

Net loss

-6,718

-9,449

-14,891

-

-

-5,280

-

Deemed dividend (see note 6)

5,442

8,451

-

-

-

-

-

Comprehensive loss

-

-

-

-

-14,347

-

-

Series A and B convertible preferred stock beneficial conversion feature accreted as a dividend

-

-

-

-

7,844

-

-

Comprehensive Loss Attributable to Common Shareholders

-

-

-

-

-22,192

-

-

Net loss attributable to common shareholders

-12,161

-17,901

-14,891

-16,998

-

-5,280

-9,802

Weighted Average Common Shares Outstanding:
Basic

-

-

7,286

27,060

-

-

-

Diluted

-

-

7,292

27,060

-

-

-

Basic and diluted

2,043

183

-

-

21,754

12,817

-

Net loss per Common Share: (see note 12)
Basic

-

-

-2.04

-0.63

-

-

-

Diluted

-

-

-2.41

-0.63

-

-

-

Basic and diluted

-5.95

-97.35

-

-

-1.02

-0.41

-